UNASSIGNED: In recent years, @entity618 ( @entity2098 )-based immunosuppressive regimen was recommended in induction and in maintenance therapy in @entity1988 ( @entity1988 ), one of the most severe and common manifestations of @entity1252 . However, no recommendations were made so far regarding monitoring of @entity3442 ( @entity3443 ) plasma concentrations. @entity734 ( @entity734 ) constitutes a practical tool to ensure optimal posology. In renal transplantation, it was proved that acute allograft rejection incidences decreased when the recommended @entity3443 target exposure has been maintained (30-60 mg  h  L). The results obtained in the field of transplant medicine indicate the potential benefit of carrying out @entity734 in @entity1988 . To date, the correlation of @entity3443 exposure and clinical outcomes in the population of @entity1988 @entity1 was the objective of just a few studies. The aim of this review was therefore to present @entity734 studies in @entity1988 @entity1 on @entity2098 therapy and to compare their results. Based on the conclusions drawn from @entity734 studies in @entity1988 , it can be suggested that the area under the concentration-time curve threshold values of 30-45 mg  h  L can potentially be associated with favorable treatment outcome. Moreover, the majority of the analyzed studies indicate relatively good correlation between trough concentration and the area under the concentration-time curve in @entity1 treated with @entity2098 that constitutes an important implication for @entity734 approach in routine setting. The threshold of 3 mg/L can potentially be recommended as a target trough value.

Therapeutic Drug Monitoring of @entity3442 in XXXX : A Review of Current Literature.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity3442 :: ('MESH:D009173', 'Chemical') :: ['mycophenolic acid'] @entity1252 :: ('MESH:D008180', 'Disease') :: ['systemic lupus erythematosus'] @entity3443 :: ('D015097', 'Chemical') :: ['MPA'] @entity1988 :: ('MESH:D008181', 'Disease') :: ['lupus nephritis', 'LN'] @entity2098 :: ('CHEBI:8764', 'Chemical') :: ['MMF'] @entity618 :: ('MESH:C063008', 'Chemical') :: ['mycophenolate mofetil'] @entity734 :: ('MESH:D019966', 'Disease') :: ['TDM', 'Therapeutic drug monitoring']
@entity1988 :: (MESH:D008181,Disease) :: ['Lupus Nephritis']
